Nivolumab as the new standard of metastatic kidney cancer treatment
The last decade was marked by the rapid development of kidney cancer drug treatment and advent of targeted drugs aimed at inhibition of angiogenesis which plays a crucial role in tumor growth. Despite certain success, targeted antiangiogenetic therapy with tyrosine kinase inhibitors, mammalian targe...
Main Author: | |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2017-10-01
|
Series: | Onkourologiâ |
Subjects: | |
Online Access: | https://oncourology.abvpress.ru/oncur/article/view/717 |